Teleios Health review

Teleios provides useful public disclosures about its clinical network and pharmacy partners, but the $99 headline is incomplete without dose, supply and continuing-payment terms. Confirm the assigned legal practice and pharmacy before paying; the full denial refund does not erase the separate post-review cancellation deduction or dispensed-medication finality.

Teleios Health, LLC describes itself in its terms as a technology platform connecting patients with independent healthcare providers and pharmacies. It is not itself the healthcare provider. The expanded public FAQ names Lion MD as the medical network and identifies Ana Lisa Carr and Kelly Tenbrink as its leaders, with published NPI numbers. These are provider disclosures, not independent license checks, and leadership names do not tell an applicant which professional practice or individual clinician will be responsible for their care. Ask for that assignment and the process for contacting the treating team. The FAQ also names Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx and The Pharmacy Hub. That is more useful than an unnamed pharmacy network, but it is still a list of possible partners. It does not identify the pharmacy that will dispense a particular prescription. This review evaluates the public purchase terms and care pathway, without claiming firsthand treatment, pharmacy inspection or medical approval.

The advertised process begins with a health questionnaire covering history, current medication and goals. An independent provider reviews the information, decides whether treatment is appropriate and, if approved, issues a prescription for delivery with instructions and supplies. The FAQ describes ongoing healthcare-provider and customer-service support. Ask how follow-up decisions are handled, which consultation formats are available and how quickly a clinical concern reaches the prescriber. Availability in all fifty states is an explicit company claim, and the coverage page lists them individually. Both that page and the FAQ qualify the claim: particular services or medicines depend on state rules and provider licensure. The telehealth consent requires patients to be physically in their home state during the consultation. A mailing address alone is therefore insufficient if the applicant is traveling. Terms require adulthood and a United States location; a universal numerical clinical eligibility threshold was not established on the reviewed pages. The consent permits an in-person visit when clinically necessary and encourages an ongoing primary-care relationship. Prescription approval is not guaranteed, regardless of completing the questionnaire or paying the program fee.

The homepage markets both compounded weekly semaglutide and tirzepatide from $99 per month. The expanded FAQ repeats $99 monthly for each and expressly includes medication, provider consultations and shipping if the provider approves treatment. That inclusion is helpful, but it leaves the central comparison unanswered: what dose and quantity does the price buy, how long does it apply, and what will the account authorize next? We did not establish a complete supply schedule, promotional duration, renewal total or dose-escalation price. The advertised amount is insufficient to budget a complete continuing prescription without those details. Obtain a written first bill and renewal bill for the specific proposed prescription before choosing on price. Teleios is self-pay. The terms say it does not participate in insurance, Medicare or Medicaid networks and divide professional fees into provider and pharmacy components. The consent requires out-of-pocket expenses to be paid before the telehealth visit. The FAQ promises a full refund if the clinician determines the patient is not suitable. Voluntary cancellation after a completed review and written prescription follows another rule: the refund policy says Teleios may refund the total less a $50 professional fee if an email arrives within twenty-four hours of the completed review. The policy’s wording does not make every request an unconditional refund entitlement. Dispensed compounded medications are nonrefundable. Concerns about dispensed medication should be raised with the pharmacy within forty-eight hours, using the label contact details. The reviewed documents did not establish a clear recurring-subscription cancellation cutoff, so ask separately how to prevent the next payment rather than assuming an order-cancellation email stops all renewals.

Teleios explicitly presents the named treatments as compounded products. Its own disclosure says compounded drugs are not FDA-approved. Brand-drug trial percentages and customer stories should not be read as proof that a particular Teleios preparation produces the same outcome. The provider and dispensing pharmacy should identify the active ingredient, concentration, prescribed dose, supply and storage instructions for the actual order. The public weekly treatment description supports an injection pathway; it does not establish an oral GLP-1 option. Terms send prescriptions to a partner pharmacy by default, while allowing patients to request an alternative by email. The consent also recognizes pharmacy choice. Ask whether changing pharmacy affects the advertised bundled charge or availability. Approved orders are said to ship within five to seven business days, with emailed tracking after shipment; this is not a promise of delivery within that period. The replacement policy is consequential: once the courier records delivery, Teleios considers fulfillment complete and says it cannot reship a package marked delivered. A lost or stolen package after that confirmation requires a new paid order under the stated policy. Plan to receive the parcel and keep the pharmacy’s handling instructions. An identified partner list improves transparency, but the specific dispensing assignment and label remain essential before treating delivery as a routine retail purchase.